EL7.AI
StocksMediumUpdated×2•Originally published 4 April 2026•Updated 5 April 2026•
1 min read

Lawsuit Filed Against uniQure Following Public Rebukes from US FDA

Key Facts

1Law firm Hagens Berman is updating its investigation into uniQure N.V. (QURE) following public rebukes from the FDA.
2The investigation involves allegations of "distorted" data provided by the company.
3A 9-day deadline alert has been issued for shareholders to take legal action.

A class action lawsuit has been officially filed against uniQure N.V. (QURE), marking a significant escalation from the initial investigation stage. The legal action follows extraordinary public rebukes from the U.S. Food and Drug Administration (FDA) regarding allegations of "distorted" and inaccurate data submissions. The lawsuit claims that the company’s leadership misled investors and compromised the integrity of its reported clinical findings. A specific court-related deadline of April 13, 2026, has now been established for shareholders to join the class action. This litigation aims to recover financial losses suffered by investors due to the alleged misrepresentations and their impact on the company's market value. Analysts expect QURE shares to remain under pressure as the legal process unfolds and regulatory scrutiny intensifies.